Date: 2012-06-19
Type of information: Licensing agreement
Compound: DNA methylation biomarker septin9
Company: Epigenomics (Germany-USA) Companion Dx Reference Lab (USA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease: colorectal cancer
Details: Epigenomics, the German-American cancer molecular diagnostics company, has signed a non-exclusive licensing agreement for its proprietary DNA methylation biomarker Septin9 with Companion Dx Reference Lab, an emerging leader in pharmacogenomic testing and cancer companion diagnostics. Under the terms of the agreement, Companion Dx has obtained rights to establish and commercialize a blood-based, laboratory-developed test (LDT) using methylated Septin9 as biomarker for the detection of colorectal cancer.
The agreement with Companion Dx complements Epigenomics’ LDT agreements with Quest Diagnostics, ARUP Laboratories and Warnex Medical Laboratories in North America. Furthermore, Abbott Molecular has worldwide, non-exclusive license to develop and to commercialize IVD test kit products while Qiagen and Sysmex have acquired options to do so.
Financial terms: Epigenomics is entitled to double digit royalties on sales.
Latest news:
